Literature DB >> 24115743

Pain characteristics and age-related pain trajectories in infants and young children with sickle cell disease.

Carlton Dampier1, Beth Ely, Darcy Brodecki, Camille Coleman, Leela Aertker, Jocelyn Andrel Sendecki, Benjamin Leiby, Karen Kesler, Terry Hyslop, Marie Stuart.   

Abstract

BACKGROUND: The epidemiology of painful episodes in infants and younger children with SCD has not been well studied, particularly for pain managed at home. PROCEDURE: SCD infants identified by newborn screening were enrolled in a longitudinal observational study of pain symptoms requiring parents to report the presence or absence of pain daily. When sickle cell related-pain events occurred, pain occurrence, location, associated symptoms and the treatment provided also were reported.
RESULTS: 103 children were enrolled at a median age of 7.2 months; 50 had an SS genotype, 32 SC, 6 SB(0)thalassemia, and 15 SB(+)thalassemia. Parents/guardians reported for a median of 3.8 years (range 0.3-7.6 years) assessing pain for a total of 141,197 days, excluding any period of recurrent transfusions, with an additional 28,079 days of missing data (16%). Children had pain reported on 2,288 days (1.6%), representing 768 distinct episodes of pain, of which 108 required hospitalizations (14%). Pain locations and symptoms consistent with dactylitis were most prevalent (80%) in the 0-12 month age group, and became progressively less prevalent thereafter. Group-based trajectory modeling of pain episode or pain day frequency identified several trajectory groups with progressively older ages of peak pain frequency, which included 40-45% of SS/SB(0)thalassemia and 10-12% of SC/SB(+)thalassemia children.
CONCLUSIONS: Pain is relatively infrequent in SCD infants and young children and commonly managed at home. Analyses of longitudinal pain trajectories suggest several different pain trajectories, differing in their frequency, age of onset, and age at peak pain frequency with clinical implications for hydroxyurea management.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  infants; pain; sickle cell disease

Mesh:

Substances:

Year:  2013        PMID: 24115743      PMCID: PMC3877174          DOI: 10.1002/pbc.24796

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  19 in total

1.  Utilization of analgesics in the multicenter study of hydroxyurea in sickle cell anemia: effect of sex, age, and geographical location.

Authors:  Samir K Ballas; Robert L Bauserman; William F McCarthy; Oswaldo L Castro; Wally R Smith; Myron A Waclawiw
Journal:  Am J Hematol       Date:  2010-08       Impact factor: 10.047

2.  Prediction of adverse outcomes in children with sickle cell disease.

Authors:  S T Miller; L A Sleeper; C H Pegelow; L E Enos; W C Wang; S J Weiner; D L Wethers; J Smith; T R Kinney
Journal:  N Engl J Med       Date:  2000-01-13       Impact factor: 91.245

3.  Recruitment and retention of children in longitudinal research.

Authors:  Beth Ely; Camille Coleman
Journal:  J Spec Pediatr Nurs       Date:  2007-07       Impact factor: 1.260

4.  Long-term alteration of pain sensitivity in school-aged children with early pain experiences.

Authors:  Christiane Hermann; Johanna Hohmeister; Sueha Demirakça; Katrin Zohsel; Herta Flor
Journal:  Pain       Date:  2006-10-02       Impact factor: 6.961

5.  Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).

Authors:  Winfred C Wang; Russell E Ware; Scott T Miller; Rathi V Iyer; James F Casella; Caterina P Minniti; Sohail Rana; Courtney D Thornburg; Zora R Rogers; Ram V Kalpatthi; Julio C Barredo; R Clark Brown; Sharada A Sarnaik; Thomas H Howard; Lynn W Wynn; Abdullah Kutlar; F Daniel Armstrong; Beatrice A Files; Jonathan C Goldsmith; Myron A Waclawiw; Xiangke Huang; Bruce W Thompson
Journal:  Lancet       Date:  2011-05-14       Impact factor: 79.321

6.  The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients.

Authors:  Wally R Smith; Samir K Ballas; William F McCarthy; Robert L Bauserman; Paul S Swerdlow; Martin H Steinberg; Myron A Waclawiw
Journal:  Pain Med       Date:  2011-04-11       Impact factor: 3.750

7.  Does neonatal surgery lead to increased pain sensitivity in later childhood?

Authors:  Jeroen W B Peters; Renata Schouw; K J S Anand; Monique van Dijk; Hugo J Duivenvoorden; Dick Tibboel
Journal:  Pain       Date:  2005-04       Impact factor: 6.961

8.  Impact of hydroxyurea on clinical events in the BABY HUG trial.

Authors:  Courtney D Thornburg; Beatrice A Files; Zhaoyu Luo; Scott T Miller; Ram Kalpatthi; Rathi Iyer; Phillip Seaman; Jeffrey Lebensburger; Ofelia Alvarez; Bruce Thompson; Russell E Ware; Winfred C Wang
Journal:  Blood       Date:  2012-08-22       Impact factor: 22.113

Review 9.  Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease.

Authors:  F M Gill; L A Sleeper; S J Weiner; A K Brown; R Bellevue; R Grover; C H Pegelow; E Vichinsky
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

10.  Caregiver report of pain in infants and toddlers with sickle cell disease: reliability and validity of a daily diary.

Authors:  Beth Ely; Carlton Dampier; Miriam Gilday; Patricia O'Neal; Darcy Brodecki
Journal:  J Pain       Date:  2002-02       Impact factor: 5.820

View more
  8 in total

1.  Frequency of Hospitalizations for Pain and Association With Altered Brain Network Connectivity in Sickle Cell Disease.

Authors:  Deepika S Darbari; Johnson P Hampson; Eric Ichesco; Nadja Kadom; Gilbert Vezina; Iordanis Evangelou; Daniel J Clauw; James G Taylor Vi; Richard E Harris
Journal:  J Pain       Date:  2015-08-18       Impact factor: 5.820

2.  Hydroxyurea Initiation Among Children With Sickle Cell Anemia.

Authors:  Sarah L Reeves; Hannah K Jary; Jennifer P Gondhi; Jean L Raphael; Lynda D Lisabeth; Kevin J Dombkowski
Journal:  Clin Pediatr (Phila)       Date:  2019-05-21       Impact factor: 1.168

Review 3.  Mast cell-neural interactions contribute to pain and itch.

Authors:  Kalpna Gupta; Ilkka T Harvima
Journal:  Immunol Rev       Date:  2018-03       Impact factor: 12.988

Review 4.  Optimizing the care model for an uncomplicated acute pain episode in sickle cell disease.

Authors:  Paul Telfer; Banu Kaya
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  Identifying Chronic Pain Subgroups in Pediatric Sickle Cell Disease: A Cluster-Analytic Approach.

Authors:  Soumitri Sil; Alison Manikowski; Mallory Schneider; Lindsey L Cohen; Carlton Dampier
Journal:  Clin J Pain       Date:  2022-10-01       Impact factor: 3.423

Review 6.  Rheumatic Manifestations of Haemoglobinopathies.

Authors:  Michael Hughes
Journal:  Curr Rheumatol Rep       Date:  2018-08-14       Impact factor: 4.592

7.  Comparative Analysis of Pain Behaviours in Humanized Mouse Models of Sickle Cell Anemia.

Authors:  Jianxun Lei; Barbara Benson; Huy Tran; Solomon F Ofori-Acquah; Kalpna Gupta
Journal:  PLoS One       Date:  2016-08-05       Impact factor: 3.240

8.  Transcriptomic analysis of gene signatures associated with sickle pain.

Authors:  Jinny A Paul; Anupam Aich; Juan E Abrahante; Ying Wang; Rebecca S LaRue; Susan K Rathe; Krystina Kalland; Aditya Mittal; Ritu Jha; Fei Peng; David A Largaespada; Anindya Bagchi; Kalpna Gupta
Journal:  Sci Data       Date:  2017-05-16       Impact factor: 6.444

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.